Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to Vaccines in RMS Participants Treated with Ozanimod
NCT05028634Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of ozanimod in relapsing-remitting multiple sclerosis (RRMS), sponsored by Celgene Corporation. Started Nov 2021; status: completed.
02
Drugs
ozanimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT05028634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028634.